Premium
Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome
Author(s) -
Roden Dan M.,
Driest Sara L.,
Mosley Jonathan D.,
Wells Quinn S.,
Robinson Jamie R.,
Denny Joshua C.,
Peterson Josh F.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1035
Subject(s) - pharmacogenetics , medical prescription , medicine , drug , genotyping , intensive care medicine , computer science , pharmacology , biology , genotype , genetics , gene
The development of new knowledge around the genetic determinants of variable drug action has naturally raised the question of how this new knowledge can be used to improve the outcome of drug therapy. Two broad approaches have been taken: a point‐of‐care approach in which genotyping for specific variant(s) is undertaken at the time of drug prescription, and a preemptive approach in which multiple genetic variants are typed in an individual patient and the information archived for later use when a drug with a “pharmacogenetic story” is prescribed. This review addresses the current state of implementation, the rationale for these approaches, and barriers that must be overcome. Benefits to pharmacogenetic testing are only now being defined and will be discussed.